Taudorf E, Laursen L C, Djurup R, Kappelgaard E, Pedersen C T, Søborg M, Wilkinson P, Weeke B
Allergy. 1985 Jul;40(5):321-35. doi: 10.1111/j.1398-9995.1985.tb00243.x.
Oral hyposensitization is still widely used in the treatment of allergic diseases, but controlled studies proving a beneficial effect are lacking. Fifty-eight hay fever patients were admitted to a double-blind placebo efficacy study in oral hyposensitization. An enterosoluble tablet containing timothy whole pollen or placebo was taken daily. Preseasonally, the actively treated patients received 4,315,000 PNU (880,260 AUR) and totally for 6 months 8,915,000 PNU (1,818,660 AUR). Such high doses have never been tried in similar studies. A new principle has been used - "the pollen count interval method" - in the evaluation of symptom and medication score. The study failed to prove any beneficial effect of oral hyposensitization measured by symptom score, medication score, nasal provocation test or skin prick test. There was no change in timothy specific IgE and IgG which could be caused by the treatment. The possibility that oral hyposensitization might be an effective treatment of hay fever in the future is discussed, but it is concluded that the present regimens cannot be recommended.
口服减敏疗法仍广泛用于过敏性疾病的治疗，但缺乏能证明其有益效果的对照研究。58名花粉热患者参加了一项口服减敏疗法的双盲安慰剂疗效研究。每天服用一片含梯牧草全花粉的肠溶片剂或安慰剂。在花粉季节前，积极治疗的患者接受4315000个花粉单位（880260个抗原单位反应），在6个月内共接受8915000个花粉单位（1818660个抗原单位反应）。如此高的剂量在类似研究中从未尝试过。在评估症状和用药评分时采用了一种新原则——“花粉计数间隔法”。该研究未能证明通过症状评分、用药评分、鼻激发试验或皮肤点刺试验衡量的口服减敏疗法有任何有益效果。治疗未引起梯牧草特异性IgE和IgG的变化。文中讨论了口服减敏疗法未来可能成为花粉热有效治疗方法的可能性，但得出的结论是目前的治疗方案不可推荐。
